ATE527345T1 - Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten - Google Patents

Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten

Info

Publication number
ATE527345T1
ATE527345T1 AT06829900T AT06829900T ATE527345T1 AT E527345 T1 ATE527345 T1 AT E527345T1 AT 06829900 T AT06829900 T AT 06829900T AT 06829900 T AT06829900 T AT 06829900T AT E527345 T1 ATE527345 T1 AT E527345T1
Authority
AT
Austria
Prior art keywords
chimeric fusion
fusion protein
nucleotide sequences
protein
sequences coding
Prior art date
Application number
AT06829900T
Other languages
English (en)
Inventor
Christian Scholz
Peter Schaarschmidt
Urban Schmitt
Elke Faatz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE527345T1 publication Critical patent/ATE527345T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
AT06829900T 2006-01-03 2006-12-29 Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten ATE527345T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06000056 2006-01-03
EP06009106 2006-05-03
PCT/EP2006/012599 WO2007077008A1 (en) 2006-01-03 2006-12-29 Chimaeric fusion protein with superior chaperone and folding activities

Publications (1)

Publication Number Publication Date
ATE527345T1 true ATE527345T1 (de) 2011-10-15

Family

ID=37908055

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06829900T ATE527345T1 (de) 2006-01-03 2006-12-29 Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten

Country Status (8)

Country Link
US (2) US7947494B2 (de)
EP (1) EP1971684B1 (de)
JP (1) JP4871960B2 (de)
CN (1) CN101351550B (de)
AT (1) ATE527345T1 (de)
CA (1) CA2636075C (de)
ES (1) ES2375863T3 (de)
WO (1) WO2007077008A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2127678A1 (de) * 2008-05-26 2009-12-02 Roche Diagnostics GmbH SlpA als Werkzeug für recombinante Protein-und Enzym-technologie
AR086250A1 (es) * 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo
EP2706115A1 (de) 2012-09-06 2014-03-12 Roche Diagnostics GmbH Chaperon-Chaperon-Fusionspolypeptide zur Reduzierung der Störungen und Stabilisierung von Immunoassays
CN104755499B (zh) * 2012-11-08 2020-10-02 霍夫曼-拉罗奇有限公司 结合HER3 β-发夹和HER4 β-发夹的抗HER3/HER4抗原结合蛋白
WO2014071978A1 (en) 2012-11-08 2014-05-15 Roche Diagnostics Gmbh Nucleic acids encoding chimeric polypeptides for library screening
CN104755500B (zh) * 2012-11-08 2020-10-02 霍夫曼-拉罗奇有限公司 结合HER3 β-发夹的HER3抗原结合蛋白
WO2015044083A1 (en) * 2013-09-27 2015-04-02 F. Hoffmann-La Roche Ag Thermus thermophilus slyd fkbp domain specific antibodies
WO2016004024A1 (en) 2014-07-02 2016-01-07 Sutro Biopharma, Inc. High growth capacity auxotrophic escherichia coli and methods of use
WO2016112295A1 (en) 2015-01-09 2016-07-14 Warp Drive Bio, Inc. Compounds that participate in cooperative binding and uses thereof
CA2974343A1 (en) * 2015-02-13 2016-08-18 Sekisui Chemical Co., Ltd. Nucleic acid, fusion protein, recombined cell, and isoprene or cyclic terpene production method
KR102943992B1 (ko) * 2015-12-15 2026-03-25 에프. 호프만-라 로슈 아게 트랜스글루타미나제 인식 부위를 갖는 fkbp 도메인
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN107522787B (zh) * 2016-06-15 2025-09-16 中国科学院上海营养与健康研究所 在细胞内产生点突变的融合蛋白、其制备及用途
WO2018161038A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il12 compositions and methods for immunotherapy
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
WO2018187423A1 (en) * 2017-04-05 2018-10-11 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
US20210210159A1 (en) * 2018-05-31 2021-07-08 Trustees Of Dartmouth College Computational protein design using tertiary or quaternary structural motifs
AU2020257185A1 (en) * 2019-04-16 2021-12-16 University Of Washington Amantadine binding protein
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
WO2023213758A1 (en) * 2022-05-03 2023-11-09 F. Hoffmann-La Roche Ag Hiv gp41 variants for immunodiagnostic assays
CN122138968A (zh) 2023-11-09 2026-06-02 罗氏诊断公司 用于标记的转谷氨酰胺酶底物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0871648A1 (de) 1995-09-15 1998-10-21 Merck & Co., Inc. Ein assay mit hohem durchsatz unter verwendung von fusionsprotein
US5989868A (en) 1997-09-12 1999-11-23 The Board Of Regents Of The University Of Oklahoma Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli
US7094884B2 (en) * 2001-06-22 2006-08-22 Roche Diagnostics Corporation Soluble complexes of amylod β peptide and peptidyl prolyl isomerase chaperone and methods of making and using them
US6962982B2 (en) * 2001-06-22 2005-11-08 Roche Diagnostics Corporation Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them
ATE522603T1 (de) * 2001-06-22 2011-09-15 Hoffmann La Roche Löslicher komplex, der retrovirale oberflächen- glykoproteine und fkpa oder slyd enthält
US7094757B2 (en) * 2001-06-22 2006-08-22 Roche Diagnostics Corporation Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them
US20050130259A1 (en) 2002-06-25 2005-06-16 Akira Ideno Expression vector, host, fused protein, process for producing fused protein and process for producing protein
WO2004092221A1 (ja) * 2003-04-18 2004-10-28 Sekisui Chemical Co. Ltd. 免疫原及び免疫用組成物、並びにそれらを使用する抗体の製造方法
US7604935B2 (en) * 2005-10-26 2009-10-20 Roche Diagnostics Operations, Inc. Soluble rubella E1 envelope protein variants

Also Published As

Publication number Publication date
ES2375863T3 (es) 2012-03-07
US20110189754A1 (en) 2011-08-04
EP1971684A1 (de) 2008-09-24
CN101351550A (zh) 2009-01-21
US8247206B2 (en) 2012-08-21
HK1128727A1 (en) 2009-11-06
JP2009521938A (ja) 2009-06-11
CA2636075A1 (en) 2007-07-12
US7947494B2 (en) 2011-05-24
WO2007077008A1 (en) 2007-07-12
US20090042251A1 (en) 2009-02-12
CN101351550B (zh) 2012-10-10
JP4871960B2 (ja) 2012-02-08
CA2636075C (en) 2011-11-08
EP1971684B1 (de) 2011-10-05

Similar Documents

Publication Publication Date Title
CY1121049T1 (el) Καινοτομες αλληλουχιες σηματος για τη βελτιωση των πρωτεϊνικων εκφρασεων και της εκκρισης των ανασυνδυασμενων ενζυμων και αλλων πρωτεϊνων
WO2010082804A3 (en) Method for producing physiologically active protein or peptide using immunoglobulin fragment
WO2013075066A3 (en) Variant serum albumin with improved half -life and other properties
ATE517914T1 (de) Dimere fusionsproteine und materialien und verfahren zu deren herstellung
CY1112924T1 (el) Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
ATE492633T1 (de) Polypeptide mit cellobiohydrolaseaktivität und dafür kodierende polynukleotide
MX348071B (es) Variantes de fc.
IL220164B (en) A method for purifying a purified antibody, antibody fragment, or fc-fused protein using an affinity chromatography matrix
WO2013040093A3 (en) Glucagon-like peptide-2 compositions and methods of making and using same
EA201390923A1 (ru) Модифицированное антитело с улучшенным полупериодом существования
EA201290722A1 (ru) Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение
WO2011146891A3 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
CA2636075A1 (en) Chimaeric fusion protein with superior chaperone and folding activities
EP4345163A3 (de) Gentechnische herstellung von nichtmenschlichen tieren zur herstellung chimärer antikörper
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
WO2008100470A3 (en) Rage - immunoglobulin fusion proteins
UA107180C2 (uk) Туберкульозний білок rv1753c, композиція, що його містить, та застосування
ATE474917T1 (de) Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
WO2011098999A3 (en) Chemical preparation of ubiquitin thioesters and modifications thereof
WO2014144911A3 (en) Hybrid immunoglobulin containing non-peptidyl linkage
PE20120415A1 (es) Anticuerpos anti-igf
NZ760008A (en) Uti fusion proteins
ATE515568T1 (de) Polypeptide mit endoglucanase-aktivtät und dafür codierende polynukleotide
UA101142C2 (ru) Способ разработки антитела
DK2059525T3 (da) Split-core-partikler til præsentation af fremmedmolekyler, især til vaccineanvendelser, og fremgangsmåde til fremstilling af disse

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1971684

Country of ref document: EP